250 related articles for article (PubMed ID: 23870722)
1. Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial.
Amminger GP; Chanen AM; Ohmann S; Klier CM; Mossaheb N; Bechdolf A; Nelson B; Thompson A; McGorry PD; Yung AR; Schäfer MR
Can J Psychiatry; 2013 Jul; 58(7):402-8. PubMed ID: 23870722
[TBL] [Abstract][Full Text] [Related]
2. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.
Amminger GP; Schäfer MR; Papageorgiou K; Klier CM; Cotton SM; Harrigan SM; Mackinnon A; McGorry PD; Berger GE
Arch Gen Psychiatry; 2010 Feb; 67(2):146-54. PubMed ID: 20124114
[TBL] [Abstract][Full Text] [Related]
3. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids.
Amminger GP; Mechelli A; Rice S; Kim SW; Klier CM; McNamara RK; Berk M; McGorry PD; Schäfer MR
Transl Psychiatry; 2015 Jan; 5(1):e495. PubMed ID: 25585167
[TBL] [Abstract][Full Text] [Related]
4. Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?
Mossaheb N; Schäfer MR; Schlögelhofer M; Klier CM; Cotton SM; McGorry PD; Amminger GP
Schizophr Res; 2013 Aug; 148(1-3):163-7. PubMed ID: 23778032
[TBL] [Abstract][Full Text] [Related]
5. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.
McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EY; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Amminger GP
JAMA Psychiatry; 2017 Jan; 74(1):19-27. PubMed ID: 27893018
[TBL] [Abstract][Full Text] [Related]
6. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study.
Zanarini MC; Schulz SC; Detke HC; Tanaka Y; Zhao F; Lin D; Deberdt W; Kryzhanovskaya L; Corya S
J Clin Psychiatry; 2011 Oct; 72(10):1353-62. PubMed ID: 21535995
[TBL] [Abstract][Full Text] [Related]
7. Supplementation of n-3 Polyunsaturated Fatty Acids for Major Depressive Disorder: A Randomized, Double-Blind, 12-Week, Placebo-Controlled Trial in Korea.
Park Y; Park YS; Kim SH; Oh DH; Park YC
Ann Nutr Metab; 2015; 66(2-3):141-148. PubMed ID: 25824637
[TBL] [Abstract][Full Text] [Related]
8. omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study.
Zanarini MC; Frankenburg FR
Am J Psychiatry; 2003 Jan; 160(1):167-9. PubMed ID: 12505817
[TBL] [Abstract][Full Text] [Related]
9. A randomized clinical trial of high eicosapentaenoic acid omega-3 fatty acids and inositol as monotherapy and in combination in the treatment of pediatric bipolar spectrum disorders: a pilot study.
Wozniak J; Faraone SV; Chan J; Tarko L; Hernandez M; Davis J; Woodworth KY; Biederman J
J Clin Psychiatry; 2015 Nov; 76(11):1548-55. PubMed ID: 26646031
[TBL] [Abstract][Full Text] [Related]
10. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol.
Qurashi I; Chaudhry IB; Khoso AB; Farooque S; Lane S; Husain MO; Chu S; Sarginson J; Hamarani M; Naqvi HA; Razzaque B; Minhas FA; Yung AR; Deakin JFW; Husain N
Trials; 2017 Nov; 18(1):524. PubMed ID: 29121974
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of omega-3 supplementation for major depression: a randomized controlled trial.
Lespérance F; Frasure-Smith N; St-André E; Turecki G; Lespérance P; Wisniewski SR
J Clin Psychiatry; 2011 Aug; 72(8):1054-62. PubMed ID: 20584525
[TBL] [Abstract][Full Text] [Related]
12. Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo-controlled, double-blind trial.
Hamazaki K; Itomura M; Huan M; Nishizawa H; Sawazaki S; Tanouchi M; Watanabe S; Hamazaki T; Terasawa K; Yazawa K
Nutrition; 2005 Jun; 21(6):705-10. PubMed ID: 15925295
[TBL] [Abstract][Full Text] [Related]
13. Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial.
Arnold C; Winter L; Fröhlich K; Jentsch S; Dawczynski J; Jahreis G; Böhm V
JAMA Ophthalmol; 2013 May; 131(5):564-72. PubMed ID: 23519529
[TBL] [Abstract][Full Text] [Related]
14. Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis.
Smesny S; Milleit B; Hipler UC; Milleit C; Schäfer MR; Klier CM; Holub M; Holzer I; Berger GE; Otto M; Nenadic I; Berk M; McGorry PD; Sauer H; Amminger GP
Mol Psychiatry; 2014 Mar; 19(3):317-24. PubMed ID: 23478748
[TBL] [Abstract][Full Text] [Related]
15. Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial.
Berger M; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Mitchell TW; Meyer BJ; Thompson A; Yung AR; McGorry PD; Amminger GP
Front Psychiatry; 2019; 10():393. PubMed ID: 31244693
[No Abstract] [Full Text] [Related]
16. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.
Markulev C; McGorry PD; Nelson B; Yuen HP; Schaefer M; Yung AR; Thompson A; Berger G; Mossaheb N; Schlögelhofer M; Smesny S; de Haan L; Riecher-Rössler A; Nordentoft M; Chen EYH; Verma S; Hickie I; Amminger GP
Early Interv Psychiatry; 2017 Oct; 11(5):418-428. PubMed ID: 26279065
[TBL] [Abstract][Full Text] [Related]
17. Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11DS genetically at high risk for psychosis. Protocol of a randomized, double-blind, placebo-controlled treatment trial.
Armando M; De Crescenzo F; Vicari S; Digilio MC; Pontillo M; Papaleo F; Amminger GP
Early Interv Psychiatry; 2016 Oct; 10(5):390-6. PubMed ID: 25345540
[TBL] [Abstract][Full Text] [Related]
18. Relationship between Erythrocyte Fatty Acid Composition and Psychopathology in the Vienna Omega-3 Study.
Kim SW; Jhon M; Kim JM; Smesny S; Rice S; Berk M; Klier CM; McGorry PD; Schäfer MR; Amminger GP
PLoS One; 2016; 11(3):e0151417. PubMed ID: 26963912
[TBL] [Abstract][Full Text] [Related]
19. Treatment with omega-3 polyunsaturated fatty acids does not improve endothelial function in patients with type 2 diabetes and very high cardiovascular risk: A randomized, double-blind, placebo-controlled study (Omega-FMD).
Siniarski A; Haberka M; Mostowik M; Gołębiowska-Wiatrak R; Poręba M; Malinowski KP; Gąsior Z; Konduracka E; Nessler J; Gajos G
Atherosclerosis; 2018 Apr; 271():148-155. PubMed ID: 29518747
[TBL] [Abstract][Full Text] [Related]
20. Omega-3 polyunsaturated fatty acids (n-3 PUFAs), somatic and fatigue symptoms in cardiovascular diseases comorbid major depressive disorder (MDD): A randomized controlled trial.
Chang JP; Chang SS; Chen HT; Chien YC; Yang HT; Huang SY; Tseng PT; Chang CH; Galecki P; Su KP
Brain Behav Immun; 2023 Aug; 112():125-131. PubMed ID: 37301235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
